Exhibit 99.1
iBio Announces Closing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 9, 2022 (GLOBE NEWSWIRE) – iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,870,192 shares of common stock and Series B warrants to purchase up to 3,870,192 shares of common stock, at a combined public offering price of $1.04 per share (or pre-funded warrant in lieu thereof) and accompanying warrants, which includes the purchase of additional warrants to purchase up to 1,009,614 shares of common stock purchased pursuant to the partial exercise of the underwriter’s option to purchase additional Series A warrants and Series B warrants to purchase. The Series A warrants have an exercise price of $1.04 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series B warrants have an exercise price of $1.04 per share, are exercisable immediately upon issuance and will expire twenty-four months from the date of issuance.
In connection with the offering, the Company granted the underwriter a 30-day option to purchase 504,807 additional shares of its common stock and/or warrants to purchase up to 1,009,614 additional shares of its common stock at the public offering price, less underwriting discounts and commissions, which the underwriter partially exercised on December 8, 2022 with respect to the warrants to purchase up to 1,009,614 additional shares of common stock.
H.C. Wainwright & Co. is acting as sole book-running manager for the public offering.
The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $3.5 million. The Company intends to use the net proceeds from the offering primarily for operating costs, including for research and development and other trial preparation expenses in addition to working capital needs and for other general corporate purposes, which may include retention and severance payments to certain of our employees or former employees and principal payments pursuant to the terms of its amended Credit Agreement.
The securities described above were offered by iBio pursuant to a shelf registration statement on Form S-3 (File No. 333-250973) that was previously filed with the Securities and Exchange Commission (the “SEC”) on November 25, 2020 and became effective on December 7, 2020. The securities have been offered only by means of a prospectus, including a prospectus supplement filed with the SEC on December 8, 2022, forming a part of the effective registration statement. Electronic copies of the final prospectus supplement and accompanying base prospectus disclosing the final terms of the offering has been filed with the SEC and may be obtained on the SEC’s website at www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Ave., New York, New York 10022, by telephone at (212) 856-5711, or by email at placements@hcwco.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iBio, Inc.
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
